Novamind reports that four health insurers are now covering its ketamine treatment for Treatment-Resistant Depression.
Senators Urge Biden To Grant Mass Pardon For Thousands Of Marijuana Cases
A group of senators is urging President Joe Biden to use his executive authority to grant a mass pardon for people with non-violent marijuana convictions, a first step toward righting the wrongs of prohibition.
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
Compass Pathways surprised and disappointed the market with its Phase IIb clinical results. Despite the immediate overall selloff on the news, the outlook for many psychedelic stocks is now BETTER.
Copper price rises on strong export growth in China
The copper price rose on Monday as worries about demand in top consumer China were offset by strong export growth data from the country.
Gold sees price gains as U.S. PPI meets expectations, but still hot
Gold and silver prices are slightly lower in early U.S. trading Monday, on routine downside corrections after recent gains.
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Compass Pathways reports successful results from its Phase IIb clinical trial of COMP360 for the treatment of Treatment Resistant Depression (TRD).
Michigan Approves Bill Expanding Access to Medical Cannabis Licenses
Michigan Gov. Gretchen Whitmer has signed legislation expanding the number of people eligible for medical cannabis licenses, including those previously barred due to a cannabis-related misdemeanor or felony.
Gold price extends gains in Pakistan
Gold rose on Monday boosted by concerns regarding uncertain economic conditions which have once again sparked a flight from risky commodities towards safer ones.
Gold, silver and platinum ready for blastoff
Gold, silver and platinum appear to be on the launching pad, ready to blast off to the upside.
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health
CYB003 is demonstrating superior treatment properties vs. an oral dosage of psilocybin.
MINDCURE Positioned For Strong Run In 2022 – CEO Q&A
MINDCURE's President and CEO, Kelsey Ramsden updates investors on iSTRYM's launch and rapid penetration, as well as drug development news on several fronts.
Trevor Gerszt: Increasing Demand Could Boost the Silver Price
One of the issues facing the purchase of any sort of asset is the uncertainty of its price.
